AC Immune S.A.
AC Immune S.A. (ACIU) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aciu · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for AC Immune S.A. (ACIU) measures how much investors pay for each dollar of the company's trailing earnings. ACIU's current PE ratio of N/A is calculated by dividing its stock price of $2.23 by its TTM earnings per share of -$0.67.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%42.8x
MedianQ3 · 75%80.2x
Max
At N/A, ACIU's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
AC Immune S.A.You ACIU | $227M | N/A | — | -$0.67 |
 Aldeyra Therapeutics, Inc. ALDX | $110M | N/A | — | -$0.56 |
 Amarin Corporation plc AMRN | $293M | N/A | — | -$1.87 |
 Annexon, Inc. ANNX | $635M | N/A | — | -$1.33 |
 Alto Neuroscience, Inc. ANRO | $632M | N/A | — | -$2.19 |
 Cellectis S.A. CLLS | $295M | N/A | — | -$0.67 |
 Contineum Therapeutics, Inc. Class A Common Stock CTNM | $420M | N/A | — | -$2.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.70 | — | |
2024-12-31 FY2024 | — | $-0.51 | — | |
2023-12-31 FY2023 | — | $-0.64 | — | |
2022-12-31 FY2022 | — | $-0.85 | — | |
2021-12-31 FY2021 | — | $-0.97 | — | |
2020-12-31 FY2020 | — | $-0.86 | — | |
2019-12-31 FY2019 | 12.80x | $0.64 | — | |
2018-12-31 FY2018 | — | $-0.82 | — | |
2017-12-31 FY2017 | — | $-0.46 | — | |
2016-12-31 FY2016 | — | $-0.14 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for AC Immune S.A. (ACIU) measures how much investors pay for each dollar of the company's trailing earnings. ACIU's current PE ratio of N/A is calculated by dividing its stock price of $2.23 by its TTM earnings per share of -$0.67.
Frequently asked questions
ACIU pe ratio · 6 questionsACIU's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.23 and TTM EPS of -$0.67. Data sourced from Financial Modeling Prep via ACIU's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AC Immune S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08